Immunocore
IMCR
149 hedge funds and large institutions have $2.68B invested in Immunocore in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 64 increasing their positions, 39 reducing their positions, and 13 closing their positions.
493% more call options, than puts
Call options by funds: $49.2M | Put options by funds: $8.29M
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
64% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 39
12% more funds holding
Funds holding: 133 → 149 (+16)
4.76% more ownership
Funds ownership: 78.01% → 82.77% (+4.8%)
5% more capital invested
Capital invested by funds: $2.56B → $2.68B (+$117M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$180M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$98.5M |
| 3 |
GA
General Atlantic
New York
|
+$38.2M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$34.3M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$24.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$69M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$41.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.8M |
| 4 |
CAC
Cowen and Company
New York
|
-$28.5M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$20.2M |
IMCR Hedge Fund Activity: Q1 2024 in Review
149 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2024, worth a combined $2.68B — up 4.6% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new IMCR positions and 13 closed out — a net gain of 16 holders — while 64 added to existing stakes and 39 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $180M. The largest seller was Baker Bros. Advisors, cutting an estimated $69M.
- 149 institutional investors held Immunocore (IMCR) as of Q1 2024, up from 133 in Q4 2023.
- Funds reported $2.68B of Immunocore stock for Q1 2024, up 4.6% quarter-over-quarter.
- 29 funds opened new Immunocore positions in Q1 2024 and 13 closed out, a net change of +16 holders.
- The largest Immunocore buyer in Q1 2024 was Fidelity Investments, an estimated $180M added.
- The largest Immunocore seller in Q1 2024 was Baker Bros. Advisors, an estimated $69M sold.
Based on aggregated 13F filings for Q1 2024.